{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-013652","form_type":"8-K","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.396080+00:00","generated_at":"2026-06-15T07:33:48.824155+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioLife Solutions Q1 revenue up 4% to $37.7M; net loss widens, explores sale of freezer lines","bullets":["Revenue $37.7M (+4% YoY); ex-COVID growth 16%; biopreservation media revenue +28%.","GAAP net loss $13.7M (-$0.32/share) vs $7.4M loss in Q1 2022; adjusted EBITDA -$1.9M.","Adjusted gross margin improved to 37% from 32% in Q4 2022; GAAP gross margin 35%.","Exploring strategic alternatives for ULT cryogenic freezer businesses, including potential divestitures.","Affirmed FY2023 revenue guidance $188-$202M (16-25% YoY growth); Q4'24 aspirational targets reaffirmed."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-013652","json":"https://secwatch.observer/filing/0001437749-23-013652.json","markdown":"https://secwatch.observer/filing/0001437749-23-013652.md","text":"https://secwatch.observer/filing/0001437749-23-013652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000143774923013652/0001437749-23-013652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000143774923013652/bioli20230510_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T07:33:48.824155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}